On May 17, 2022 Sanofi reported that New research at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from June 3-7 underscores it’s commitment to improving care across its core focus areas, including multiple myeloma, lung and breast cancers (Press release, Sanofi, MAY 17, 2022, View Source [SID1234614715]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dietmar Berger
Chief Medical Officer, Global Head of Development at Sanofi
"Oncology is a core area for Sanofi, as evidenced by the doubling of our pipeline between 2019 and 2022. As we continue to pursue transformative research to develop advanced medicines for people living with cancer, our portfolio has grown to more than ten therapies in clinical trials. In parallel, we continue to leverage external innovation through strategic collaborations and investments in cutting edge technologies. Over ten value-creating acquisitions and business development deals in the past two years have reshaped our footprint in oncology, expanding our capacities with leading talent, as well as state-of-the-art molecules and technologies in immuno-oncology, molecular oncology, and genomic medicine."
Safety and efficacy data for tusamitamab ravtansine add to growing body of evidence for our potential first-in-class therapy for the treatment of nonsquamous non-small cell lung cancer (NSQ NSCLC) with CEACAM5 expression*
Abstract 9039: Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with NSQ NSCLC expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Early clinical data for Sarclisa (isatuximab) in combination with pomalidomide-dexamethasone highlight potential for subcutaneous administration by an on-body delivery system for the treatment of relapsed refractory multiple myeloma (RRMM)
Abstract 8025: Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with RRMM: Interim phase 1b study results
Updates on trials for amcenestrant, an oral selective estrogen receptor degrader (SERD), for the potential treatment of breast cancer*
Abstract TPS607: Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)
Abstract 528: AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2- primary breast cancer
Biomarker research for SAR444881, a potential first-in-class anti-ILT2 monoclonal antibody*
Abstract 2571: Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy
Trial in progress for investigational use of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Abstract TPS9592: C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy (RT) in patients with high-risk CSCC
Libtayo is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Safety and efficacy data for SAR439459, a transforming growth factor beta (TGF-β) inhibitor*
Abstract 2524: Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors
Immunogenomic analysis for IL-2-based immunotherapies*
Publication Only: Detailed immunogenomic analysis of high dose IL-2 pharmacodynamic effects: A benchmark for next-generation IL-2-based immunotherapies
Health economics and outcomes research in NSCLC
Publication Only: Insights into the advanced non-small cell lung cancer patient journey: Treatment decision-making, preferences, and quality of life considerations
Click here to view these abstracts located in the ASCO (Free ASCO Whitepaper) Meeting Library.
*These assets are currently under investigation and their safety and efficacy has not been fully evaluated by any health authority.